CrossRef
Open Access
2025
BEHOLD-1: A phase 1 dose escalation study of GSK5733584, a B7-H4–targeted antibody–drug conjugate, in patients with advanced solid tumors, including dose expansion in patients with endometrial and platinum-resistant ovarian cancer
William McKean
Phuong Dinh
Dhanusha Sabanathan
Alina Goetz
Julie Holden
+7 lainnya
Penulis (12)
W
William McKean
P
Phuong Dinh
D
Dhanusha Sabanathan
A
Alina Goetz
J
Julie Holden
S
Shruti Shah
J
Jeremy Waight
F
Francisco Jose Gonzalez Carreras
A
Antonio Riccio
M
Morrys C. Kaisermann
J
Jennifer Veneris
M
Minal Barve
Format Sitasi
McKean, W., Dinh, P., Sabanathan, D., Goetz, A., Holden, J., Shah, S. et al. (2025). BEHOLD-1: A phase 1 dose escalation study of GSK5733584, a B7-H4–targeted antibody–drug conjugate, in patients with advanced solid tumors, including dose expansion in patients with endometrial and platinum-resistant ovarian cancer. https://doi.org/10.1016/j.ygyno.2025.04.143
Akses Cepat
PDF tidak tersedia langsung
Cek di sumber asli →Informasi Jurnal
- Tahun Terbit
- 2025
- Bahasa
- en
- Sumber Database
- CrossRef
- DOI
- 10.1016/j.ygyno.2025.04.143
- Akses
- Open Access ✓